EUVIMEDEUVIMED entdecken
Open Access

Chondroitin sulfate proteoglycan 4 increases invasion of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma by modifying transforming growth factor-β signalling

Allison R K Macaulay, Jianbo Yang, Matthew A Price, Colleen L Forster, Megan J Riddle, Christen L Ebens, Frank W Albert, Alessio Giubellino, James B McCarthy, Jakub Tolar

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljae295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Allison R K Macaulay und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Blood and Marrow Transplant and Cellular Therapy, Department of Pediatrics, Medical School, University of Minnesota, MN,USA. Hauptthemen laut MEDLINE: Skin Neoplasms, Epidermolysis Bullosa Dystrophica, Carcinoma, Squamous Cell, Signal Transduction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Elsa Pardee Foundation, NCATS NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic skin-blistering disorder that often progresses to metastatic cutaneous squamous cell carcinoma (cSCC) at chronic wound sites. Chondroitin sulfate proteoglycan 4 (CSPG4) is a cell-surface proteoglycan that is an oncoantigen in multiple malignancies, where it modulates oncogenic signalling, drives epithelial-to-mesenchymal transition (EMT) and enables cell motility.

Objectives

To evaluate CSPG4 expression and function in RDEB cSCC.

Methods

RDEB cSCC cell lines were used to assess CSPG4-dependent changes in invasive potential, transforming growth factor (TGF)-β1-stimulated signal activation and clinically relevant cytopathology metrics in an in vitro full-thickness tumour model. CSPG4 expression in RDEB cSCC and non-RDEB cSCC tumours was analysed via immunohistochemistry and single-cell RNA sequencing (scRNA-Seq), respectively.

Results

Inhibiting CSPG4 expression reduced invasive potential in multiple RDEB cSCC cell lines and altered membrane-proximal TGF-β signal activation via changes in SMAD3 phosphorylation. CSPG4 expression was uniformly localized to basal layer keratinocytes in fibrotic RDEB skin and tumour cells at the tumour–stroma interface at the invasive front in RDEB cSCC tumours in vivo. Analysis of published scRNA-Seq data revealed that CSPG4 expression was correlated with an enhanced EMT transcriptomic signature in cells at the tumour–stroma interface of non-RDEB cSCC tumours. Cytopathological metrics, for example nucleus : cell area ratio, were influenced by CSPG4 expression in in vitro tumour models.

Conclusions

We determined that CSPG4 expression in RDEB cSCC cell lines enhanced the invasive potential of tumours. Mechanistically, CSPG4 was found to enhance membrane-proximal TGF-β-stimulated signalling via SMAD3, which is a key mediator of EMT in RDEB cSCC. The implication of these studies is that CSPG4 may represent a therapeutic target that can be leveraged for the clinical management of patients with RDEB cSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsEpidermolysis Bullosa DystrophicaCarcinoma, Squamous CellSignal TransductionNeoplasm InvasivenessChondroitin Sulfate ProteoglycansHumansCell Line, TumorEpithelial-Mesenchymal TransitionTransforming Growth Factor betaKeratinocytesSmad3 ProteinTransforming Growth Factor beta1Cell MovementMembrane ProteinsChondroitin Sulfate Proteoglycan 4

Substanzen

Chondroitin Sulfate ProteoglycansTransforming Growth Factor betaSmad3 ProteinTransforming Growth Factor beta1Membrane ProteinsCSPG4 protein, humanChondroitin Sulfate Proteoglycan 4SMAD3 protein, human

Autor:innen und Institutionen

  • Division of Blood and Marrow Transplant and Cellular Therapy, Department of Pediatrics, Medical School, University of Minnesota, MN,USA.
  • Department of Genetics, Cell Biology, and Genetics, University of Minnesota, MN, USA.
  • The Cancer Center, Union Hospital, Fujian Medical University, Fuzhou, China.
  • Masonic Cancer Center, University of Minnesota, MN, USA.
  • Department of Laboratory Medicine and Pathology, University of Minnesota, MN, USA.
  • Biorepository and Laboratory Services, Clinical and Translational Science Institute, University of Minnesota, MN, USA.

Förderung

  • Elsa Pardee Foundation
  • NCATS NIH HHS
  • NIAMS NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Center for Advancing Translational Sciences

Zitieren

APA

Macaulay, A. R. K., Yang, J., Price, M. A., Forster, C. L., Riddle, M. J., Ebens, C. L., Albert, F. W., Giubellino, A., McCarthy, J. B., & Tolar, J. (2024). Chondroitin sulfate proteoglycan 4 increases invasion of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma by modifying transforming growth factor-β signalling. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae295

Vancouver

Macaulay ARK, Yang J, Price MA, Forster CL, Riddle MJ, Ebens CL, et al. Chondroitin sulfate proteoglycan 4 increases invasion of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma by modifying transforming growth factor-β signalling. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae295

BibTeX
@article{Macaulay2024,
  author = {Macaulay, Allison R K and Yang, Jianbo and Price, Matthew A and Forster, Colleen L and Riddle, Megan J and Ebens, Christen L and Albert, Frank W and Giubellino, Alessio and McCarthy, James B and Tolar, Jakub},
  title = {Chondroitin sulfate proteoglycan 4 increases invasion of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma by modifying transforming growth factor-β signalling},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljae295}
}
Kostenlos starten →